Back to database

Retatrutide

Also known as: LY3437943, Triple G

GLP-1 / Weight LossPhase 3 Clinical TrialsSubcutaneous

A triple-hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Shows the highest weight loss of any obesity drug in trials.

Molecular Weight

~4700 Da

Half-Life

~6 days

Sequence

Triple agonist: GLP-1/GIP/Glucagon receptor

Mechanism of Action

Triple agonism provides complementary metabolic effects: GLP-1 suppresses appetite, GIP enhances insulin sensitivity, glucagon increases energy expenditure and fat oxidation.

Dosing Protocol

Titration from 1mg weekly, increasing monthly to 4mg, 8mg, up to 12mg weekly.

Open peptide calculator
Reconstitution

Research-grade: 5mg vial + 2mL BAC water.

Storage

Refrigerate 2-8°C. Do not freeze.

Side Effects
  • ●Nausea
  • ●Diarrhea
  • ●Vomiting
  • ●Constipation
  • ●Injection site reactions
Key Research Findings
  • ●Phase 2: up to 24.2% body weight loss at 48 weeks (highest recorded)
  • ●Superior glycemic control vs semaglutide in early data
  • ●Significant reduction in liver fat content

Research Use Only

This information is provided for educational and research purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before using any research compounds.